Mon - Fri 8:00 am - 6:00 pm
admin@hackettfirm.com
Call Us: (415) 410-9931
Mon - Fri 8:00 am - 6:00 pm
admin@hackettfirm.com
Call Us: (415) 410-9931
A landmark Harvard Medical School study published in 2024 linked semaglutide (Ozempic/Wegovy) to a significantly elevated risk of a rare, blinding eye condition. If you suffered sudden vision loss or were diagnosed with NAION while taking a GLP-1 drug, you may have a substantial claim. Fill out the form for more information »
💊 Defendant: Novo Nordisk
👁️ Condition: NAION (Sudden Vision Loss)
📍 Federal & California Courts
Semaglutide (GLP-1) Vision Loss Litigation
Ozempic · Wegovy · Rybelsus
JAMA Ophthalmology, July 2024
Harvard / Mass Eye and Ear
Active
Novo Nordisk A/S
Novo Nordisk Inc. (US)
Hackett Law Firm is actively recruiting plaintiffs who suffered sudden vision loss or were diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION) while taking semaglutide-based drugs — including Ozempic, Wegovy, and Rybelsus — manufactured by Novo Nordisk. A peer-reviewed study published in JAMA Ophthalmology in July 2024 found that semaglutide users faced dramatically elevated rates of NAION compared to non-users, raising serious questions about whether Novo Nordisk adequately warned patients of this risk.
“Nonarteritic anterior ischemic optic neuropathy — sudden, permanent vision loss caused by a loss of blood flow to the optic nerve. It is the most common cause of acute optic nerve injury in adults over 50 and, in most cases, causes irreversible blindness in the affected eye.”
Products involved in active litigation:
💉 Ozempic (semaglutide injection)
⚖️ Wegovy (semaglutide injection)
Semaglutide — sold as Ozempic for diabetes and Wegovy for weight loss — became one of the fastest-growing drug categories in modern pharmaceutical history. Novo Nordisk generated over $21 billion in combined Ozempic and Wegovy revenue in 2023 alone. However, the rapid, widespread adoption of semaglutide preceded adequate long-term safety data, and serious ocular side effects were not included as warnings on the original or updated drug labels.
In July 2024, a peer-reviewed study by researchers at Mass Eye and Ear (a Harvard Medical School affiliate) published in JAMA Ophthalmology found that semaglutide users had significantly elevated rates of NAION. The finding triggered waves of new litigation and FDA safety review requests from ophthalmology advocacy groups.
Researchers hypothesize that semaglutide’s effects on blood pressure, blood flow, and vascular dynamics may reduce perfusion to the optic nerve — particularly in individuals with existing vascular risk factors such as hypertension, sleep apnea, or a “crowded” optic disc anatomy. Because NAION typically presents as sudden painless vision loss upon waking, many patients do not initially connect the event to their medication.
The following conditions are the focus of active semaglutide ocular injury litigation:
If you were prescribed Ozempic, Wegovy, or Rybelsus and subsequently experienced sudden vision loss or were diagnosed with NAION, you may have a viable failure-to-warn and products liability claim against Novo Nordisk. The 2024 Harvard study provides substantial support for a causal link that was not disclosed to patients at the time of prescription.
Both diabetic patients prescribed Ozempic and overweight individuals prescribed Wegovy for weight management are eligible for case evaluation. Our attorneys will review your prescription history and medical records at no cost.
Our legal team alleges that Novo Nordisk knew or should have known of the elevated NAION risk associated with semaglutide, and failed to include adequate warnings on drug labeling or in communications to prescribing physicians. Claims include failure to warn, negligent product design, negligent misrepresentation, and violations of California consumer protection statutes.
This is an actively emerging litigation. Early plaintiffs who retain counsel while the science is fresh and before broader consolidation typically have the strongest positioning in eventual settlement or trial proceedings.
Complaint 01/26/26
In no case will any plaintiff ever be asked to pay any out-of-pocket sum. Hackett Law Firm handles all Ozempic / Wegovy vision loss cases on a contingency fee basis — we only get paid if and when we secure compensation for you. In the event a settlement or judgment is reached, the court will determine a reasonable legal fee from that recovery. You pay nothing upfront, ever.